Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
Resource Type
Article
Authors
Gao, Xiangyu ; Xu, Nong ; Li, Ziyu ; Shen, Lin ; Ji, Ke ; Zheng, Zhong ; Liu, Dan ; Lou, Hanmei ; Bai, Li ; Liu, Tianshu ; Li, Yunxia ; Li, Yuzhi ; Fan, Qingxia ; Feng, Mei ; Zhong, Haijun ; Huang, Yi ; Lou, Ge ; Wang, Jing ; Lin, Xiaoyan ; Chen, Ye ; An, Ruifang ; Li, Changzheng ; Zhou, Qi ; Huang, Xin ; Guo, Zengqing ; Wang, Shubin ; Li, Guiling ; Fei, Junwei ; Zhu, Lijing ; Zhu, Hong ; Li, Xiumin ; Li, Fenghu ; Liao, Sihai ; Min, Qinghua ; Tang, Lei ; Shan, Fei ; Gong, Jifang ; Gao, Yunong ; Zhou, Jun ; Lu, Zhihao ; Li, Xiaofan ; Li, Jianjie ; Ren, Hui ; Liu, Xiaohong ; Yang, Hongxia ; Li, Wenting ; Song, Weifeng ; Wang, Zhongmin Maxwell ; Li, Baiyong ; Xia, Michelle ; Wu, Xiaohua ; Ji, Jiafu
Source
In The Lancet Oncology October 2023 24(10):1134-1146
Subject
Primary Research Articles
Language
ISSN
1470-2045